New York, June 23, 2026, 08:05 EDT
- Catheter Precision drew heavy early attention after Monday announcements on new patents, a Flyte sports partnership and a resale-share registration filing.
- Google Finance showed VTAK at $1.17 in premarket trade, up 34.5% from Monday’s $0.87 close; regular NYSE trading was set for 9:30 a.m. EDT.
- The company’s S-1 registered 68.1 million shares for resale, about 25 times the 2.69 million shares outstanding listed in the filing.
Catheter Precision Inc. shares were in focus before Tuesday’s NYSE American open after traders chased the micro-cap medical-device company on a run of patent, aviation and securities-filing news.
The move matters now because VTAK is tiny. Finance data put the company’s market value at about $2.34 million, leaving the stock more exposed than larger listed companies to sharp swings in low-dollar buying and selling.
Premarket trading, the period before the main U.S. stock session, can exaggerate those moves because fewer shares usually change hands. Google Finance showed Catheter Precision at $1.17 before the open, versus Monday’s $0.8697 close, while volume on Monday was already far above normal at more than 21 million shares.
The company said Monday morning it had received or was awaiting issuance of patents covering heart-failure technology and vascular closure, the sealing of a vessel after a catheter procedure. The batch included eight heart-failure patents and three U.S. vascular-closure patents tied to LockeT, a product Catheter says it markets in the United States and Europe.
Chief Executive David Jenkins said the grants “validated” years of work and could “fortify the offerings” as Catheter discusses a possible sale of those technologies. The company gave no valuation or deal terms. GlobeNewswire
Later Monday, Flyte, Catheter Precision’s regional air-mobility unit, announced a partnership with sports agency GSE Worldwide and PGA Tour player Emiliano Grillo that began at the 2026 U.S. Open. Marc Sellouk, Flyte’s CEO, said “regional travel” is a core part of an athlete’s schedule and called the tie-up a “natural fit.” Stock Titan
That has pushed Catheter into an unusual two-track story: cardiac electrophysiology — the treatment and mapping of abnormal heart rhythms — plus private aviation. In its S-1, the company said it acquired all of Flyte and Ponderosa Air earlier this year, adding a private-aviation segment built around short-haul charter flights and brokerage services.
The competitive read-through is mostly on the aviation side. Volato Group, a private-aviation platform in which Flyte has invested, closed a $2.2 million private investment in public equity, or PIPE, at 34 cents a share, with strategic investors led by Catheter Precision; Volato CFO Mark Heinen said the financing gave the company “additional capital flexibility.” Business Wire
Volato and flyExclusive give some scale for comparison. Finance data put Volato’s market value at about $2.7 million and flyExclusive’s at about $91.8 million, against Catheter Precision’s roughly $2.3 million. That makes VTAK’s aviation push material to its story even though its legacy business is medical technology.
But the filing cuts the other way. Catheter’s S-1 registered 68,067,042 shares for resale by selling stockholders and said the company would not receive proceeds from those sales; resale registration means existing holders get a path to sell shares publicly, not that the company is selling new stock for cash.
The same filing warned that issuing the covered shares could cause substantial dilution — meaning existing holders would own a smaller percentage of the company — and said Catheter had about $441,000 in cash at March 31, a working-capital deficit of about $18.5 million and “substantial doubt” about its ability to continue as a going concern, a term auditors use when a company may lack enough funding to keep operating. SEC
Stocktwits reported that Catheter Precision traded nearly 61% higher overnight and that retail sentiment on its platform had improved to “extremely bullish.” The test now is whether that early buying survives the regular session, where investors will have to weigh patents and Flyte publicity against dilution risk, cash needs and the still-unclear economics of the company’s private-aviation pivot. stocktwits.com
